Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors

Published:2020-12 Issue: Volume:150 Page:178-185
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Zhou Yue^ORCID,Wang Bo,Qu Jinghan,Yu Fan,Zhao Yang,Li Shuyan,Zeng Ya,Yang Xi,Chu Li,Chu Xiao,Li Yida,Zou Liqing,Guo Tiantian,Ye Luxi^ORCID,Liang Fei,Wang Shengping,Liu Quan,Ni Jianjiao^ORCID,Zhu Zhengfei

Funder

Shanghai Science and Technology Committee

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference41 articles.

1. Global cancer statistics, 2012;Torre;CA. Cancer J. Clin.,2015

2. The biology and management of non-small cell lung cancer;Herbst;Nature,2018

3. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER);Shi;J. Thoracic Oncol.,2014

4. Clinical outcome of ALK-positive Non-small cell lung cancer (NSCLC) patients with De Novo EGFR or KRAS Co-mutations receiving tyrosine kinase inhibitors (TKIs);Schmid;J. Thoracic Oncol.,2017

5. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers;Shigematsu;J. Natl. Cancer Inst.,2005

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis;Heliyon;2024-05

2. Risk prediction model for postoperative brain metastasis in IIB-IIIB non-small cell lung cancer: based on radiomics and clinicopathology;2024-02-22

3. Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT;Journal of Cancer Research and Clinical Oncology;2024-02-19

4. Combination of Anti-Angiogenic and Systemic Therapy in Advanced Non-Small Cell Lung Cancer: Before and After Progression to Leptomeningeal Metastasis;2024-02-02

5. Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies;Current Oncology Reports;2024-01